FIG. 1



cell surface receptor
mAb1-(L-SO1861)n
mAb2-toxin
Endosome pH<5

FIG. 2A



SK-BR-3 (HER2++)
Relative cell viability (Untr. = 100%)
100
75
50
25
0
0,1
1
10
100
1000
Pertuzumab/Pertuzumab-SO1861/Trastuzumab-SO1861 (nM)

FIG. 2B



MDA-MB-468 (HER-)
125
100
75
50
25
0
0,1
1
10
100
1000
Pertuzumab/Pertuzumab-SO1861/Trastuzumab-SO1861 (nM)
Pertuzumab
Pertuzumab + 50 pM Trastuzumab-Saporin
Pertuzumab-SO1861
Pertuzumab-SO1861 + 50 pM Trastuzumab-Saporin
Trastuzumab-SO1861 + 50 pM Trastuzumab-Saporin

FIG. 3A



SK-BR-3 (HER2+++)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Trastuzumab-Saporin (pM)

FIG. 3B



MDA-MB-468 (HER2-)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Trastuzumab-Saporin (pM)
Trastuzumab-Saporin
Trastuzumab-Saporin + 2.5 nM Pertuzumab
Trastuzumab-Saporin + 75 nM Pertuzumab
Trastuzumab-Saporin + 2.5 nM Pertuzumab-SO1861
Trastuzumab-Saporin + 75 nM Pertuzumab-SO1861
Trastuzumab-Saporin + 2.5 nM Trastuzumab
Trastuzumab-Saporin + 75 nM Trastuzumab
Trastuzumab-Saporin + 2.5 nM Trastuzumab-SO1861
Trastuzumab-Saporin + 75 nM Trastuzumab-SO1861

FIG. 4A



SK-BR-3 (HER2+++)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
0,1
1
10
100
1000
Pertuzumab/Pertuzumab-SO1861/Trastuzumab-SO1861 (nM)

FIG. 4B



MDA-MB-468 (HER2-)
125
100
75
50
25
0
0,1
1
10
100
1000
Pertuzumab/Pertuzumab-SO1861/Trastuzumab-SO1861 (nM)
Pertuzumab
Pertuzumab + 50 pM Pertuzumab-Dianthin
Pertuzumab-SO1861
Pertuzumab-SO1861 + 50 pM Pertuzumab-Dianthin
Trastuzumab-SO1861 + 50 pM Pertuzumab-Dianthin

FIG. 5A



SK-BR-3 (HER2+++)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Pertuzumab-Dianthin (pM)

FIG. 5B



MDA-MB-468 (HER2-)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Pertuzumab-Dianthin (pM)
Pertuzumab-Dianthin
Pertuzumab-Dianthin + 25 nM Pertuzumab
Pertuzumab-Dianthin + 2.5 nM Pertuzumab-SO1861
Pertuzumab-Dianthin + 25 nM Pertuzumab-SO1861
Pertuzumab-Dianthin + 2.5 nM Trastuzumab-SO1861
Pertuzumab-Dianthin + 25 nM Trastuzumab-SO1861

FIG. 6A



A431 (EGFR++)
125
100
75
50
25
0
Relative cell viability (Untr. = 100%)
0,1
1
10
100
1000
Matuzumab/Matuzumab-SO1861/Cetuximab-SO1861 (nM)

FIG. 6B



A2058 (EGFR-)
125
100
75
50
25
0
0,1
1
10
100
1000
Matuzumab/Matuzumab-SO1861/Cetuximab-SO1861 (nM)
Matuzumab
Matuzumab + 10 pM Cetuximab-Saporin
Matuzumab + 10 pM EGF-Dianthin
Matuzumab-SO1861
Matuzumab-SO1861 + 10 pM Cetuximab-Saporin
Matuzumab-SO1861 + 10 pM EGF-Dianthin
Cetuximab-SO1861 + 10 pM Cetuximab-Saporin
Cetuximab-SO1861 + 10 pM EGF-Dianthin

FIG. 7A



A431 (EGFR+++)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Cetuximab-Saporin (pM)

FIG. 7B



A2058 (EGFR-)
125
100
75
50
25
0
0,00001
0,0001
0,001
0,01
0,1
1
10
100
1000
10000
Cetuximab-Saporin (pM)
Cetuximab-Saporin
Cetuximab-Saporin + 10 nM Matuzumab
Cetuximab-Saporin + 75 nM Matuzumab
Cetuximab-Saporin + 10 nM Matuzumab-SO1861
Cetuximab-Saporin + 75 nM Matuzumab-SO1861
Cetuximab-Saporin + 2.5 nM Cetuximab
Cetuximab-Saporin + 75 nM Cetuximab
Cetuximab-Saporin + 10 nM Cetuximab-SO1861
Cetuximab-Saporin + 75 nM Cetuximab-SO1861

FIG. 8A



A431 (EGFR++/HER2+/-/CD71+)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
1
10
100
1000
10000
SO1861 (nM)
SO1861
SO1861 + 10 pM CD71-Saporin
SO1861 + 10 pM Cetuximab-Saporin
SO1861 + 10 pM Matuzumab-Dianthin
SO1861 + 10 pM Pertuzumab-Saporin
SO1861 + 50 pM Pertuzumab-Saporin
SO1861 + 50 pM Trastuzumab-Saporin

FIG. 8B



A2058 (EGFR-/HER2+/-/CD71+)
125
100
75
50
25
0
1
10
100
1000
10000
SO1861 (nM)
SO1861
SO1861 + 10 pM CD71-Saporin
SO1861 + 10 pM Cetuximab-Saporin
SO1861 + 10 pM Matuzumab-Dianthin
SO1861 + 10 pM Pertuzumab-Saporin
SO1861 + 50 pM Pertuzumab-Saporin
SO1861 + 50 pM Trastuzumab-Saporin

FIG. 9A




SK-BR-3, (HER2++/EGFR+/CD71+)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
1
10
100
1000
10000
SO1861 (nM)
SO1861
SO1861 + 10 pM CD71-Saporin
SO1861 + 10 pM Cetuximab-Saporin
SO1861 + 10 pM Matuzumab-Dianthin
SO1861 + 10 pM Pertuzumab-Saporin
SO1861 + 50 pM Pertuzumab-Saporin
SO1861 + 50 pM Trastuzumab-Saporin

FIG. 9B


MDA-MB-468, (HER2-/EGFR++/CD71+)
125
100
75
50
25
0
1
10
100
1000
10000
SO1861 (nM)
SO1861
SO1861 + 10 pM CD71-Saporin
SO1861 + 10 pM Cetuximab-Saporin
SO1861 + 10 pM Matuzumab-Dianthin
SO1861 + 10 pM Pertuzumab-Saporin
SO1861 + 50 pM Pertuzumab-Saporin
SO1861 + 50 pM Trastuzumab-Saporin